Literature DB >> 9065133

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.

W H Kutteh1.   

Abstract

OBJECTIVE: The purpose of this study was to compare the use of low-dose aspirin alone with heparin and low-dose aspirin in the treatment of the antiphospholipid antibody syndrome. STUDY
DESIGN: A prospective, single-center trial included 50 patients who were alternately assigned to treatment. Each patient had at least three consecutive spontaneous pregnancy losses, positive antiphospholipid antibodies on two occasions, and a complete evaluation. Data were compared by chi(2) analysis and Fisher's exact test.
RESULTS: Viable infants were delivered of 11 of 25 (44%) women treated with aspirin and 20 of 25 (80%) women treated with heparin and aspirin (p < 0.05). There were no significant differences between the low-dose aspirin and the heparin plus low-dose aspirin groups with respect to gestational age at delivery (37.8 +/- 2.1 vs 37.2 +/- 3.4 weeks), number of cesarean sections (18% vs 20%), or complications.
CONCLUSION: Heparin plus low-dose aspirin provides a significantly better pregnancy outcome than low-dose aspirin alone does for antiphospholipid antibody-associated recurrent pregnancy loss.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9065133     DOI: 10.1016/s0002-9378(96)70610-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  66 in total

Review 1.  Treatment of the antiphospholipid antibody syndrome: progress in the last five years?

Authors:  M Petri
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 4.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 5.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

6.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Heparin and aspirin versus aspirin alone for prevention of recurrent pregnancy loss.

Authors:  Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

8.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

9.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 10.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.